Plain-English translation of NCT06538896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether two medications given together — Tislelizumab and nab-paclitaxel — can help treat advanced triple-negative breast cancer that has spread to the bones. The study will look at how well this combination works and whether it is safe for patients who have not yet received treatment for their advanced cancer.
Triple-negative breast cancer is a particularly aggressive type of breast cancer that is harder to treat with standard therapies. When it spreads to the bones, it can cause serious complications. This trial exists to find out if this new medication combination offers hope for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every 3 weeks to receive the medications through an IV infusion and to have checkups and blood tests. The treatment includes two intravenous medications given on a regular schedule, along with another medication to help protect your bones. You would be asked to keep track of your symptoms and report any side effects at each visit. The study involves about 20 patients total across multiple hospitals.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China